156 related articles for article (PubMed ID: 1608013)
21. The six questions of pathogen reduction technology: an overview of current opinions.
Solheim BG; Seghatchian J
Transfus Apher Sci; 2008 Aug; 39(1):51-7. PubMed ID: 18614401
[TBL] [Abstract][Full Text] [Related]
22. Blood component therapy and changing transfusion triggers.
Williford PD; Bensky KP
CRNA; 1994 Nov; 5(4):139-50. PubMed ID: 7881351
[TBL] [Abstract][Full Text] [Related]
23. [Heparinized venous approaches].
Arnáiz Betolaza L; Novoa Vences E
Rev Enferm; 1996 May; 19(213):64-5. PubMed ID: 8716873
[No Abstract] [Full Text] [Related]
24. Minimizing donor exposure in hemotherapy.
AuBuchon JP
Arch Pathol Lab Med; 1994 Apr; 118(4):380-91. PubMed ID: 8166588
[TBL] [Abstract][Full Text] [Related]
25. International forum on 'Perioperative blood salvage': a Spanish contribution.
Muñoz M; Gómez-Luque A; Ramírez G;
Vox Sang; 2007 Jan; 92(1):90. PubMed ID: 17181596
[No Abstract] [Full Text] [Related]
26. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop.
Klein HG; Glynn SA; Ness PM; Blajchman MA;
Transfusion; 2009 Jun; 49(6):1262-8. PubMed ID: 19392769
[TBL] [Abstract][Full Text] [Related]
27. Transfusion and coagulation: an overview and recent advances in practice modalities. Part II: Pharmacologic adjuncts, cell salvage mechanisms, alternatives in blood donation.
Viets JL; Yawn DH
Nurse Anesth; 1990 Dec; 1(4):206-20. PubMed ID: 2285731
[TBL] [Abstract][Full Text] [Related]
28. Bio- (hemo- plus eco-) compatibility of blood collection- and apheresis harness.
Nydegger UE
Beitr Infusionsther; 1991; 28():152-8. PubMed ID: 1725613
[No Abstract] [Full Text] [Related]
29. [Indications for labile blood products].
Jeanne M; Rasonglès P
Rev Prat; 2001 Jun; 51(12):1318-27. PubMed ID: 11503505
[TBL] [Abstract][Full Text] [Related]
30. Pathogen reduction technology.
Rock G
Transfus Apher Sci; 2008 Aug; 39(1):1. PubMed ID: 18619904
[No Abstract] [Full Text] [Related]
31. Administration of blood products.
McMahon M
Int J Trauma Nurs; 2000; 6(3):95-100. PubMed ID: 10891848
[No Abstract] [Full Text] [Related]
32. Practice Guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy.
Anesthesiology; 1996 Mar; 84(3):732-47. PubMed ID: 8659805
[TBL] [Abstract][Full Text] [Related]
33. Blood banking and transfusion medicine for the nephrologist.
Wehrli G
Semin Dial; 2012; 25(2):114-8. PubMed ID: 22276991
[TBL] [Abstract][Full Text] [Related]
34. Transfusion therapy in acquired coagulopathies.
Humphries JE
Hematol Oncol Clin North Am; 1994 Dec; 8(6):1181-201. PubMed ID: 7860444
[TBL] [Abstract][Full Text] [Related]
35. Bacterial contamination of cellular blood components: risks, sources and control.
Blajchman MA
Vox Sang; 2004 Jul; 87 Suppl1():98-103. PubMed ID: 15200616
[No Abstract] [Full Text] [Related]
36. TRALI risk reduction: donor and component management strategies.
Eder AF; Benjamin RJ
J Clin Apher; 2009; 24(3):122-9. PubMed ID: 19365816
[TBL] [Abstract][Full Text] [Related]
37. An overview of the rationale, process, and nursing implications of peripheral blood stem cell transplantation.
Walker F; Roethke SK; Martin G
Cancer Nurs; 1994 Apr; 17(2):141-8. PubMed ID: 8019998
[TBL] [Abstract][Full Text] [Related]
38. [Apheresis donation. Current views and perspectives].
Schooneman F
Transfus Clin Biol; 2005 Jun; 12(2):208-11. PubMed ID: 15925528
[No Abstract] [Full Text] [Related]
39. Neonatal blood component therapy.
Armentrout D; Getz SL
J Perinat Neonatal Nurs; 1998 Dec; 12(3):50-66. PubMed ID: 10326433
[TBL] [Abstract][Full Text] [Related]
40. Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment.
Svae TE; Neisser-Svae A; Bailey A; Reichl H; Biesert L; Schmidt T; Heger A; Römisch J
Transfus Apher Sci; 2008 Aug; 39(1):59-67. PubMed ID: 18619902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
